Weight Loss And Obesity Management Market, by Product and Services (Drugs, Supplements, Equipment, Services), by Age Group (Children, Adults, Geriatric), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Jul 2023

Code : CMI3448

Pages :170

Formats :

Excel and PDF

Industry : Medical Devices

Market News

Global Weight Loss And Obesity Management Market: Key Developments

Effective use of weight loss and obesity management products for effective control and management of obesity and weight loss is expected to drive the global weight loss and obesity management market growth over the forecast period. For instance, in July 2022, Herbalife International of America, Inc., a provider of healthcare and nutrition products, launched its new product Fat Release, to support its consumers' healthy and active lifestyles.
On March 2, 2023, PRISTYN CARE, a healthcare service provider, announced that it has entered into a strategic partnership with Allurion, a company developing a medical device for weight loss, in order to offer a weight-loss and obesity care platform.
In June 2021, Novo Nordisk A/S, a global healthcare company, announced that the U.S. Food and Drug Administration (FDA) has approved Wegovy (the brand name for once-weekly semaglutide 2.4 mg injection in the U.S.) for chronic weight management.
In December 2022, Amgen Inc., announced new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule. This first-in-human study was designed to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic effects of AMG 133 in people with obesity and without diabetes.